Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy

被引:64
作者
Van Leth, F
Kappelhoff, BS
Johnson, D
Losso, MH
Boron-Kaczmarska, A
Saag, MS
Livrozet, JM
Hall, DB
Leith, J
Huitema, ADR
Wit, FW
Beijnen, JH
Lange, JMA
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Int Antiviral Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[3] Marcia St Practice, Johannesburg, South Africa
[4] JM Ramos Mejia Hosp, Serv Immunocomprometidos, Buenos Aires, DF, Argentina
[5] Pomeranian Med Acad, Dept Infect Dis, Szczecin, Poland
[6] Univ Alabama, AIDS Outpatient Clin, Birmingham, AL USA
[7] Hop Edouard Herriot, Lyon, France
[8] Boehringer Ingelheim, Ridgefield, CT USA
[9] Boehringer Ingelheim GmbH, Ingelheim, Germany
关键词
D O I
10.1089/aid.2006.22.232
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Optimal adherence is essential for successful antiretroviral therapy. We analyzed the relation between minimum plasma drug concentration (C-min) and total drug exposure over 24 hr (AUC(24)) with virologic failure for therapy-adherent patients in the nevirapine (NVP) and efavirenz (EFV) groups of the double nonnucleoside study (2NN), which compared the efficacy of NVP and/or EFV together with stavudine and lamivudine. The objective was to find cutoff values of the C-min and AUC(24) below which the risk of virologic failure increased. The relation between C-min and AUC(24) with virologic failure (never a plasma viral load [pVL] <50 copies/ml or a rebound to two consecutive pVL >50 copies/ml) was analyzed with proportional hazard analyses. Data were censored at end of study or change of allocated treatment. The risk of virologic failure with NVP (n = 511) started to increase at a C-min <3.1 mg/L (hazard ratio [HR], 1.33; 95% confidence interval [CI], 0.89-1.97), but there was no cutoff value below which a statistically significant increased risk occurred. Neither was such a cutoff point identified for the AUC(24). The risk of virologic failure with EFV (n = 312) was significantly increased at a C-min <1.1 mg/L (HR, 1.95; 95% CI, 1.08-3.54) and an AUC(24) <40 mg.hr.L-1 (HR, 1.95; 95% CI, 1.07-3.54). Both cutoff values represent the median values for adherent patients. These associations were driven by patients from Thailand. Adjusting for geographical region made the association between C-min and AUC(24) with virologic failure statistically nonsignificant. The sensitivity of the C-min values was too low (29% for NVP, 64% for EFV) to be an adequate predictor for virologic failure. We conclude that identifying the C-min value for the sole purpose of predicting virologic failure in patients who report to be adherent to NVP or EFV is questionable because of the absence of a concentration-response relation (NVP) or the low sensitivity for such a cutoff value (NVP and EFV).
引用
收藏
页码:232 / 239
页数:8
相关论文
共 35 条
[1]   Therapeutic drug monitoring - An aid to optimising response to antiretroviral drugs? [J].
Aarnoutse, RE ;
Schapiro, JM ;
Boucher, CAB ;
Hekster, YA ;
Burger, DM .
DRUGS, 2003, 63 (08) :741-753
[2]   Position paper on therapeutic drug monitoring of antiretroviral agents [J].
Acosta, EP ;
Gerber, JG .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :825-834
[3]  
Altman DG, 1996, Practical Statistics for Medical Research
[4]  
BEAL S, 1998, NONNMEM USERS GUIDES
[5]   GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy [J].
Bossi, P ;
Peytavin, G ;
Ait-Mohand, H ;
Delaugerre, C ;
Ktorza, N ;
Paris, L ;
Bonmarchand, M ;
Cacace, R ;
David, DJ ;
Simon, A ;
Lamotte, C ;
Marcelin, AG ;
Calvez, V ;
Bricaire, F ;
Costagliola, D ;
Katlama, C .
HIV MEDICINE, 2004, 5 (05) :352-359
[6]   Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals [J].
Burger, D ;
Hugen, P ;
Reiss, P ;
Gyssens, I ;
Schneider, M ;
Kroon, F ;
Schreij, G ;
Brinkman, K ;
Richter, C ;
Prins, J ;
Aarnoutse, R ;
Lange, J .
AIDS, 2003, 17 (08) :1157-1165
[7]   Pros and cons of therapeutic drug monitoring of antiretroviral agents [J].
Burger, DM ;
Aarnoutse, RE ;
Hugen, PWH .
CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (01) :17-22
[8]  
CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141
[9]   PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results [J].
Clevenbergh, P ;
Garraffo, R ;
Durant, J ;
Dellamonica, P .
AIDS, 2002, 16 (17) :2311-2315
[10]   Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population [J].
de Vries-Sluijs, TEMS ;
Dieleman, JP ;
Arts, D ;
Huitema, ADR ;
Beijnen, JH ;
Schutten, M ;
van der Ende, ME .
CLINICAL PHARMACOKINETICS, 2003, 42 (06) :599-605